drugset / Trial / NCT01383538
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this phase I study to determine the optimal dose for the combination of IPI-926 plus FOLFIRINOX (5-fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) chemotherapy in patients with pancreatic cancer.
Timeline
- Start
- 2011-08-23
- Primary completion
- 2012-12-13
- Completion
- 2015-05-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 120 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | Patidegib | Small molecule | 130 mg | Oral |
| Subject | Patidegib | Small molecule | 160 mg | Oral |
| Subject | fluorouracil | Small molecule | 1600 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |